

Cont.
a

P1 1. treating a cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-inhibitor or plasmin-inhibitor and ^{heparin} ~~heparin~~ to remove cold soluble plasma protein;

P1 2. dissolving the purified precipitate;

L 3. adding human albumin to the resulting solution; and

P1 4. lyophilizing the solution. — 7

~~2p~~ 8. A method as described in claim 7 wherein the cryoprecipitate is treated once with said buffer solution. — 9

~~2p~~ 9. A method as described in claim 7 wherein the cryoprecipitate is treated several times with said buffer solution. — 7

END

R E M A R K S

The applicants have reviewed the Examiner's comments in the Office Action mailed October 20, 1981. Applicants note that claims 12-14 have been withdrawn from consideration but will maintain them in this application until and if a divisional application directed to those claims is filed. At page 2, paragraph 3 of the Office Action the Examiner stated that "claim 8 stands withdrawn from further consideration by the Examiner". Applicants do not understand this statement since claim 8 is clearly one of the claims elected for consideration in this case.

12
-3-

In light of the Examiner's comments, claims 1-11 have been cancelled and new claims 15-23 have been added to the specification.

Claim 1 has been rewritten as claim 15 which clearly recite the presence of fibrinogen, albumin and cold-insoluble globulin as required by the Examiner. Support for this amendment is found at page 5, lines 11-14 and claim 8.

The preferred amount of plasminogen-activator-inhibitor has been deleted from claim 1 and included in new claim 17. It is clear from page 4, line 7 that the specific amount of the plasminogen-activator-inhibitor is not critical but rather preferred.

The Examiner has also rejected claims 1-7 and 9-11 under 35 U.S.C. §112 stating that the claims should be limited to the disclosure at page 5, lines 11-14 of the specification. Claim 15 has been rewritten to recite the presence of fibrinogen, albumin and cold-insoluble globulin. The ratio of fibrinogen to albumin to cold-insoluble globulin recited at page 5, line 14 is a preferred embodiment specifically claimed in claim 20, but applicants submit that this preferred ratio need not be included in broad claim 15. The specification at page 3, lines 24-7 and page 4, lines 1-10 define the invention as containing fibrinogen and albumin in a ratio of 33 to 90:5 to 40. The ratio of cold-insoluble globulin to fibrinogen and albumin is not indicated to be critical to

This is the first request for an extension of time and is not being made for the purpose of delay.

The original and one copy of this request is enclosed. It is respectfully requested that the Examiner, or another duly authorized officer of the Patent and Trademark Office, grant this request by indicating his approval on the copy and returning the same in the attached self-addressed stamped envelope.

Respectfully submitted,



Arthur S. Tenser
Patent Office Reg. No. 18,839



M. Andrea Ryan
Patent Office Reg. No. 28,469

Attorneys for Applicants
(212) 489-3356

Approved

JAN 20 1982

Deputy 
SPA, Group 140